Close Menu

NEW YORK (360Dx) — Swedish biopharmaceutical firm BioArctic announced today that it has partnered with Brain Biomarker Solutions (BBS) to develop new biomarkers and diagnostic methods for Alzheimer's disease.

Under the terms of the deal, BioArctic will work with BBS — a spinout of the University of Gothenburg — to identify and measure new blood- and cerebrospinal fluid-based biomarkers that can be used to diagnose Alzheimer's disease and monitor the effects of investigational treatments for the condition.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test. 

Apr
16
Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.